UB-165 je lek koji deluje kao agonist neuronskih nikotinskih acetilholinskih receptora. On je pun agonist za α3β2 i parcijalni agonist za α4β2 izoformu. Ovaj ligand se koristi za izučavanje uloge ovih podtipova receptora u oslobađanju dopamina i noradrenalina u mozgu.[3][4] On je takođe služio kao vodeće jedinjenje za razvoj brojnih drugih selektivnih liganda nikotinskih receptora.[5][6][7][8]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Sharples, C. G.; Kaiser, P.; Soliakov; Marks; Collins; Washburn; Wright; Spencer i dr.. (2000). „UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes”. Journal of Neuroscience20 (8): 2783–2791. PMID10751429.
↑Gohlke, H.; Gündisch; Schwarz; Seitz; Tilotta; Wegge (2002). „Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo4.2.1non-2-ene UB-165”. Journal of Medicinal Chemistry45 (5): 1064–1072. DOI:10.1021/jm010936y. PMID11855986.
↑Sharples, C. G.; Karig; Simpson; Spencer; Wright; Millar; Wonnacott; Gallagher (2002). „Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (+/-)-UB-165”. Journal of Medicinal Chemistry45 (15): 3235–3245. DOI:10.1021/jm020814l. PMID12109907.
↑Sutherland, A.; Gallagher, T.; Sharples, C.; Wonnacott, S. (2003). „Synthesis of two fluoro analogues of the nicotinic acetylcholine receptor agonist UB-165”. The Journal of Organic Chemistry68 (6): 2475–2478. DOI:10.1021/jo026698b. PMID12636420.
↑Karig, G.; Large; Sharples; Sutherland; Gallagher; Wonnacott (2003). „Synthesis and nicotinic binding of novel phenyl derivatives of UB-165. Identifying factors associated with alpha7 selectivity”. Bioorganic & Medicinal Chemistry Letters13 (17): 2825–2828. DOI:10.1016/S0960-894X(03)00594-8. PMID14611837.